The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
Study Type
OBSERVATIONAL
Enrollment
721
OVAnex is a multivarite index assay assessing ovarian cancer risk
Women's Health Arizona
Chandler, Arizona, United States
Altus Research
Lake Worth, Florida, United States
MidTown OBGYN
Columbus, Georgia, United States
Premier OBGYN of Minnesota
Eden Prairie, Minnesota, United States
OVAnex
OVAnex is a multivariate index assay assessing ovarian cancer risk. The Ovanex MIA uses seven biomarkers with a stepwise algorithm to generate a risk score which ranges from 0 to 20.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Square Care Health
New Hyde Park, New York, United States
Northwell Health
New Hyde Park, New York, United States
Seven Hills Clinical Research Group
Cincinnati, Ohio, United States
May Grant OB/GYN
Lancaster, Pennsylvania, United States
Hill Country OBGYN Associates
Austin, Texas, United States